Health approves ‘Jardiance’ (Boehringer Ingelheim and Lilly) for patients with chronic kidney disease

#Health #approves #Jardiance #Boehringer #Ingelheim #Lilly #patients #chronic #kidney #disease

The Alianza Boehringer Ingelheim y Lilly announced this Wednesday that the Ministry of Health has approved the financing of ‘Jardiance’ (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), which has been shown to reduce the risk of progression of kidney disease or cardiovascular death, as well as as the risk of hospitalization for any cause.

As explained at a press conference, it is a drug that was already used in Spain to treat patients with type 2 diabetes and heart failure. It will be available for new use in ERC from this Friday.

Hospitalizations account for one-third to one-half of total healthcare costs for people with CKD. In total, it affects 1 in 7 people in Spain, which represents a 15% of the population.

[La enfermedad renal crónica, silenciosa hasta que los riñones casi dejan de funcionar.]

Since the initial phases of the disease occur without symptoms, many people may not be aware that they have it. In fact, it is estimated that 2 out of 3 patients are undiagnosed.

Additionally, CKD doubles the risk of hospitalization and is one of the leading causes of death worldwide. In Spain, caring for the most advanced stages of chronic kidney disease requires almost 3% of the health expenditure of the National Health System (SNS) and 4% from specialized hospital care.

Renal disease

People with chronic kidney disease experience a reduction quality of life in advanced stages of the disease, often due to the high burden of symptoms and treatments.

Likewise, the depression It affects up to one-third of the overall diagnosed kidney population and is most commonly diagnosed in people with advanced kidney disease.

Early diagnosis of chronic kidney disease is an appropriate and cost-effective intervention for the NHS. Although we are referring to a silent disease, we know the risk factors that increase the probability of its development.

“It is Early approach may reduce risk of deteriorating kidney function kidney failure and hospitalizations,” said Dr. José Luis Górriz, head of the Nephrology Service at the Valencia University Clinical Hospital.